» Articles » PMID: 24651556

The Role of Oxytocin in Psychiatric Disorders: a Review of Biological and Therapeutic Research Findings

Overview
Specialty Psychiatry
Date 2014 Mar 22
PMID 24651556
Citations 100
Authors
Affiliations
Soon will be listed here.
Abstract

After participating in this educational activity, the physician should be better able to 1. Identify the biological role of oxytocin in forming attachments. 2. Evaluate the relationship between various neuropsychiatric disorders and oxytocin. 3. Identify clinical implications of using oxytocin to treat various neuropsychiatric disorders. Oxytocin is a peptide hormone integral in parturition, milk letdown, and maternal behaviors that has been demonstrated in animal studies to be important in the formation of pair bonds and in social behaviors. This hormone is increasingly recognized as an important regulator of human social behaviors, including social decision making, evaluating and responding to social stimuli, mediating social interactions, and forming social memories. In addition, oxytocin is intricately involved in a broad array of neuropsychiatric functions and may be a common factor important in multiple psychiatric disorders such as autism, schizophrenia, and mood and anxiety disorders. This review article examines the extant literature on the evidence for oxytocin dysfunction in a variety of psychiatric disorders and highlights the need for further research to understand the complex role of the oxytocin system in psychiatric disease and thus pave the way for developing new therapeutic modalities. Articles were selected that involved human participants with various psychiatric disorders and that either compared oxytocin biology to healthy controls or examined the effects of exogenous oxytocin administration.

Citing Articles

Salivary oxytocin and amygdalar alterations in functional neurological disorders.

Weber S, Stoffel N, Ansede-Bermejo J, Cruz R, Del Real Bolt A, Bruckmaier R Brain Commun. 2024; 7(1):fcae455.

PMID: 39726815 PMC: 11670354. DOI: 10.1093/braincomms/fcae455.


Interactions of Oxytocin and Dopamine-Effects on Behavior in Health and Disease.

Petersson M, Uvnas-Moberg K Biomedicines. 2024; 12(11).

PMID: 39595007 PMC: 11591571. DOI: 10.3390/biomedicines12112440.


Contrasting Effects of Oxytocin on MK801-Induced Social and Non-Social Behavior Impairment and Hyperactivity in a Genetic Rat Model of Schizophrenia-Linked Features.

Sampedro-Viana D, Canete T, Ancil-Gascon P, Cisci S, Tobena A, Fernandez-Teruel A Brain Sci. 2024; 14(9).

PMID: 39335415 PMC: 11430565. DOI: 10.3390/brainsci14090920.


Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets.

Yates J Subst Abuse Rehabil. 2024; 15:125-161.

PMID: 39228432 PMC: 11370775. DOI: 10.2147/SAR.S431273.


Oxytocin pathway gene variation and corticostriatal resting-state functional connectivity.

Xiao S, Fischer H, Ebner N, Rukh G, Dang J, Westberg L Compr Psychoneuroendocrinol. 2024; 20:100255.

PMID: 39211730 PMC: 11357861. DOI: 10.1016/j.cpnec.2024.100255.


References
1.
Scott A, Shering P, Legros J, Whalley L . Improvement in depressive illness is not associated with altered release of neurophysins over a course of ECT. Psychiatry Res. 1991; 36(1):65-73. DOI: 10.1016/0165-1781(91)90118-9. View

2.
Bartz J, Zaki J, Bolger N, Hollander E, Ludwig N, Kolevzon A . Oxytocin selectively improves empathic accuracy. Psychol Sci. 2010; 21(10):1426-8. PMC: 6634294. DOI: 10.1177/0956797610383439. View

3.
Linkowski P, Geenen V, Kerkhofs M, Mendlewicz J, Legros J . Cerebrospinal fluid neurophysins in affective illness and in schizophrenia. Eur Arch Psychiatry Neurol Sci. 1984; 234(3):162-5. DOI: 10.1007/BF00461555. View

4.
Churchland P, Winkielman P . Modulating social behavior with oxytocin: how does it work? What does it mean?. Horm Behav. 2011; 61(3):392-9. PMC: 3312973. DOI: 10.1016/j.yhbeh.2011.12.003. View

5.
Legros J, Gazzotti C, Carvelli T, Franchimont P, Timsit-Berthier M, von Frenckell R . Apomorphine stimulation of vasopressin- and oxytocin-neurophysins. Evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics. Psychoneuroendocrinology. 1992; 17(6):611-7. DOI: 10.1016/0306-4530(92)90019-4. View